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The use of agonist antibodies to costimulatory receptors
holds significant promise as a complementary approach
to the already proven strategy of antibody mediated
checkpoint blockade. This is in part due to the multiple
mechanisms that have been associated with targeting
costimulatory molecules in mouse models such as
expansion of antigen-specific effector T cells (Teff),
decrease in number or functional activity of regulatory
T cells (Treg), and activation of NK cells. Recent reports
have suggested that reduction of intratumoral Treg was
particularly important for the anti-tumor activity of several
immune modulating antibodies.
We have developed an agonist anti-human CD27 anti-
body, varlilumab, and have previously demonstrated its
anti-tumor efficacy in several syngeneic tumor models
using human CD27 transgenic mice. We set out to under-
stand which mechanism of action of the CD27 antibody is
related to its anti-tumor activity by developing mouse iso-
type variants of the antibody. Varlilumab expressed as a
mouse IgG1 isotype (varli-mG1) induces potent costimula-
tion and has no depleting activity, whereas, varlilumab
expressed as a mouse IgG2a isotype (varli-mG2a) has
moderate costimulatory activity and is capable of depleting
cells with high CD27 expression (e.g. Treg). We found that
as monotherapy, varli-mG1 was very effective in the BCL1
lymphoma model, and ineffective in the EG.7 thymoma
model. In contrast, varli-mG2a was ineffective in the BCL1
model, but had anti-tumor activity in the EG.7 model.
Based on correlative flow cytometry studies, we hypothe-
size that depleting Treg with high CD27 expression is the
primary mechanism for anti-CD27 therapy in the EG.7
model, whereas the BCL1 model responds to potent CD27
costimulation. Interestingly, varlilumab (human IgG1 iso-
type) has a combination of the costimulation and Treg
depleting activity and has potent anti-tumor activity in
both models.
These data suggest that the mechanism of anti-tumor
immunity induced by varlilumab is model dependent,
and we are currently investigating this in additional
tumor models. The results imply that multiple mechan-
isms are likely to also be relevant in the human setting.
The preclinical studies and results from the Phase I trial
with varlilumab are consistent with the antibody’s capa-
city to mediate both T cell activation and a reduction in
the number of Treg.
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